Logo image of HOTH

HOTH THERAPEUTICS INC (HOTH) Stock Overview

NASDAQ:HOTH - US44148G2049 - Common Stock

1.465 USD
+0.14 (+10.15%)
Last: 9/8/2025, 12:21:15 PM

HOTH Key Statistics, Chart & Performance

Key Statistics
52 Week High3.8
52 Week Low0.65
Market Cap19.43M
Shares13.26M
Float12.70M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.07
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10/amc
IPO02-15 2019-02-15
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


HOTH short term performance overview.The bars show the price performance of HOTH in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30

HOTH long term performance overview.The bars show the price performance of HOTH in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 -40 -60 -80

The current stock price of HOTH is 1.465 USD. In the past month the price increased by 23.11%. In the past year, price increased by 33.18%.

HOTH THERAPEUTICS INC / HOTH Daily stock chart

HOTH Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 44.58 681.47B
JNJ JOHNSON & JOHNSON 17.84 429.61B
AZN ASTRAZENECA PLC-SPONS ADR 18.24 251.05B
NVS NOVARTIS AG-SPONSORED ADR 14.55 249.29B
NVO NOVO-NORDISK A/S-SPONS ADR 14.01 243.39B
MRK MERCK & CO. INC. 10.88 209.29B
PFE PFIZER INC 7.24 139.49B
SNY SANOFI-ADR 10.46 113.23B
BMY BRISTOL-MYERS SQUIBB CO 6.88 94.20B
GSK GSK PLC-SPON ADR 8.82 80.27B
ZTS ZOETIS INC 24.48 67.49B
TAK TAKEDA PHARMACEUTIC-SP ADR 52 47.63B

About HOTH

Company Profile

HOTH logo image Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The firm also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).

Company Info

HOTH THERAPEUTICS INC

1177 Avenue Of The Americas, 5Th Floor Suite 5066

New York City NEW YORK 10020 US

CEO: Robb Knie

Employees: 3

HOTH Company Website

HOTH Investor Relations

Phone: 16467562997

HOTH THERAPEUTICS INC / HOTH FAQ

What is the stock price of HOTH THERAPEUTICS INC today?

The current stock price of HOTH is 1.465 USD. The price increased by 10.15% in the last trading session.


What is the ticker symbol for HOTH THERAPEUTICS INC stock?

The exchange symbol of HOTH THERAPEUTICS INC is HOTH and it is listed on the Nasdaq exchange.


On which exchange is HOTH stock listed?

HOTH stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for HOTH THERAPEUTICS INC stock?

7 analysts have analysed HOTH and the average price target is 4.08 USD. This implies a price increase of 178.5% is expected in the next year compared to the current price of 1.465. Check the HOTH THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is HOTH THERAPEUTICS INC worth?

HOTH THERAPEUTICS INC (HOTH) has a market capitalization of 19.43M USD. This makes HOTH a Nano Cap stock.


How many employees does HOTH THERAPEUTICS INC have?

HOTH THERAPEUTICS INC (HOTH) currently has 3 employees.


What are the support and resistance levels for HOTH THERAPEUTICS INC (HOTH) stock?

HOTH THERAPEUTICS INC (HOTH) has a support level at 1.29 and a resistance level at 1.48. Check the full technical report for a detailed analysis of HOTH support and resistance levels.


Should I buy HOTH THERAPEUTICS INC (HOTH) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does HOTH THERAPEUTICS INC (HOTH) stock pay dividends?

HOTH does not pay a dividend.


When does HOTH THERAPEUTICS INC (HOTH) report earnings?

HOTH THERAPEUTICS INC (HOTH) will report earnings on 2025-11-10, after the market close.


What is the Price/Earnings (PE) ratio of HOTH THERAPEUTICS INC (HOTH)?

HOTH THERAPEUTICS INC (HOTH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.07).


What is the Short Interest ratio of HOTH THERAPEUTICS INC (HOTH) stock?

The outstanding short interest for HOTH THERAPEUTICS INC (HOTH) is 2.01% of its float. Check the ownership tab for more information on the HOTH short interest.


HOTH Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to HOTH. When comparing the yearly performance of all stocks, HOTH is one of the better performing stocks in the market, outperforming 81.88% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

HOTH Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to HOTH. No worries on liquidiy or solvency for HOTH as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

HOTH Financial Highlights

Over the last trailing twelve months HOTH reported a non-GAAP Earnings per Share(EPS) of -1.07. The EPS increased by 33.95% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -100.8%
ROE -104.57%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%29.17%
Sales Q2Q%N/A
EPS 1Y (TTM)33.95%
Revenue 1Y (TTM)N/A

HOTH Forecast & Estimates

7 analysts have analysed HOTH and the average price target is 4.08 USD. This implies a price increase of 178.5% is expected in the next year compared to the current price of 1.465.


Analysts
Analysts82.86
Price Target4.08 (178.5%)
EPS Next Y60.12%
Revenue Next YearN/A

HOTH Ownership

Ownership
Inst Owners2.31%
Ins Owners0.49%
Short Float %2.01%
Short Ratio0.7